# Systemic Lupus Erythematous 

Eva Niklinska

## Background

- Characterized by multisystem inflammation, activation of complement,
    autoantibody formation

- Presentation:

<!-- -->

    - Constitutional: fatigue, fevers, weight loss

    - Neurologic: cerebritis, myelitis, mononeuritis multiplex, psychosis

    - Skin: malar rash (spares nasolabial folds), discoid lesions
        (scarring), photosensitivity

    - Hematologic: leukopenia, anemia, thrombocytopenia

    - Pulmonary: pleuritis, pleural effusion, ILD

    - Cardiac: pericarditis/myocarditis, increased risk for CAD,
        Libman-Sacks endocarditis

    - Renal: nephritic/nephrotic syndrome

    - MSK: arthralgias, myalgias, arthritis (nonerosive, often symmetric)

    - Ophtho: keratoconjunctivitis sicca 2/2 concurrent Sjogren’s

## Evaluation

- Labs to check upon admission: dsDNA (don’t re-send ANA/ENA panel if
    known ddx), C3/C4, ESR, CRP, CBC w/ diff, CMP, UPC

- 2019 EULAR/ACR classification criteria for diagnosis:

    - ANA (≥ 1:80) + additive scoring (classify as SLE if score is 10+)

    - Do not count criteria if there is a more likely explanation for it

    - Occurrence of a criterion on one occasion is sufficient. Criteria do
        not need to occur simultaneously. At least one criterion must be
        clinical

- Ddx: RA, MCTD, SS, Sjogren’s, Vasculitis (Behcet’s), PM/DM,
    Fibromyalgia 

- \* Note + ANA is now entry criteria \[ANA only needs to be + once\]

<table>
<colgroup>
<col style="width: 46%" />
<col style="width: 9%" />
<col style="width: 31%" />
<col style="width: 11%" />
</colgroup>
<thead>
<tr class="header">
<th>Clinical Criteria</th>
<th>Weight</th>
<th>Laboratory Criteria</th>
<th>Weight</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td><p><em>Constitutional</em></p>
<p>Fever</p></td>
<td>2</td>
<td><p><em><strong>Antiphospholipid antibodies</strong></em></p>
<p>(Lupus AC, CL, β2GP1)</p></td>
<td>2</td>
</tr>
<tr class="even">
<td><p><em>Hematologic</em></p>
<p>Leukopenia</p>
<p>Thrombocytopenia</p>
<p>Autoimmune hemolysis</p></td>
<td><p>3</p>
<p>4</p>
<p>4</p></td>
<td><p><em><strong>Complement proteins</strong></em></p>
<p>Low C3 OR C4</p>
<p>Low C3 AND C4</p>
<p><em><strong>SLE-specific antibodies</strong></em></p></td>
<td><p>3</p>
<p>4</p></td>
</tr>
<tr class="odd">
<td><p><em>Neuropsychiatric</em></p>
<p>Delirium</p>
<p>Psychosis</p>
<p>Seizure</p></td>
<td><p>2</p>
<p>3</p>
<p>4</p></td>
<td><p>Anti-dsDNA OR</p>
<p>Anti-Smith</p></td>
<td>6</td>
</tr>
<tr class="even">
<td><p><em>Mucocutaneous</em></p>
<p>Non-scarring alopecia</p>
<p>Oral ulcers</p>
<p>Subacute cutaneous OR discoid lupus</p>
<p>Acute cutaneous lupus</p></td>
<td><p>2</p>
<p>2</p>
<p>4</p>
<p>6</p></td>
<td></td>
<td></td>
</tr>
<tr class="odd">
<td><p><em>Serosal</em></p>
<p>Pleural or pericardial effusion</p>
<p>Acute pericarditis</p></td>
<td><p>5</p>
<p>6</p></td>
<td></td>
<td></td>
</tr>
<tr class="even">
<td><p><em>Musculoskeletal</em></p>
<p>Joint involvement (2+ joints)</p></td>
<td>6</td>
<td></td>
<td></td>
</tr>
<tr class="odd">
<td><p><em>Renal</em></p>
<p>Proteinuria (&gt;0.5g/24h)</p>
<p>Renal Bx Class II or V lupus nephritis</p>
<p>Renal Bx Class III or IV lupus nephritis</p></td>
<td><p>4</p>
<p>8</p>
<p>10</p></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

## Management

- Hydroxychloroquine mainstay of treatment, 200-400 mg/day; dose 5
    mg/kg/day for long term to decrease risk of retinal toxicity

    - Safe in pregnancy; decreases VTE/HLD risk 

    - Annual ophtho exam for retinal toxicity 

    - NOT immunosuppressive

- Glucocorticoids for flares: Usually started with hydroxychloroquine
    and tapered once hydroxychloroquine has taken effect

- Other immunosuppressive medications (MTX, MMF, AZA, RTX) used with
    rheumatology consultation: MMF, cyclophosphamide or other advanced
    therapies used in SLE with renal involvement or severe end organ
    involvement
